Detalhe da pesquisa
1.
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.
Blood
; 143(19): 1931-1936, 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38364112
2.
Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML.
Blood
; 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38691678
3.
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.
Blood
; 142(20): 1697-1707, 2023 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37595359
4.
Overlapping features of therapy-related and de novo NPM1-mutated AML.
Blood
; 141(15): 1846-1857, 2023 04 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36508705
5.
A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemia.
Br J Haematol
; 196(6): 1337-1343, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34957541
6.
Molecular MRD status and outcome after transplantation in NPM1-mutated AML.
Blood
; 135(9): 680-688, 2020 02 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-31932839
7.
Use of an anti-CD200-blocking antibody improves immune responses to AML in vitro and in vivo.
Br J Haematol
; 193(1): 155-159, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32996123
8.
Assessment of Minimal Residual Disease in Standard-Risk AML.
N Engl J Med
; 374(5): 422-33, 2016 Feb 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-26789727
9.
Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome.
Blood
; 140(22): 2407-2411, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35960851
10.
A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.
Blood
; 129(9): 1143-1154, 2017 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27872058
11.
Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia.
Blood
; 125(19): 2985-94, 2015 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-25805812
12.
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.
J Clin Oncol
; 42(10): 1158-1168, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38215358
13.
Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia.
Br J Haematol
; 160(2): 188-98, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23167276
14.
Nuclear factor I-C overexpression promotes monocytic development and cell survival in acute myeloid leukemia.
Leukemia
; 37(2): 276-287, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36572750
15.
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial.
Blood Adv
; 7(16): 4539-4549, 2023 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37171402
16.
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML.
Leukemia
; 37(10): 2066-2072, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37558736
17.
The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA.
Blood
; 115(5): 948-56, 2010 Feb 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-19965647
18.
Protein Kinase C Epsilon Overexpression Is Associated With Poor Patient Outcomes in AML and Promotes Daunorubicin Resistance Through p-Glycoprotein-Mediated Drug Efflux.
Front Oncol
; 12: 840046, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35707351
19.
RUNX3 overexpression inhibits normal human erythroid development.
Sci Rep
; 12(1): 1243, 2022 01 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35075235
20.
Increased expression of RUNX3 inhibits normal human myeloid development.
Leukemia
; 36(7): 1769-1780, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35490198